Triple-Drug cocktail aims to tackle rare cancer
NCT ID NCT07156019
First seen Jun 24, 2026 · Last updated Jun 26, 2026 · Updated 1 time
Summary
This phase 2 trial tests a combination of three drugs—sintilimab, surufatinib, and temozolomide—in 32 people with advanced neuroendocrine carcinoma that has worsened after prior treatment. The goal is to see if the combination can shrink tumors and control the disease. Participants receive the drugs in 21-day cycles for up to 24 months.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- sintilimab, surufatinib, and temozolomide
- What this could lead to
- If successful, this combination could offer a new treatment option to shrink tumors and delay progression in advanced neuroendocrine carcinoma.
- What could go wrong
- This is a small, early-phase study with only 32 participants. The combination may cause significant side effects, and results may not apply to all patients.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NEUROENDOCRINE CARCINOMAS (NEC) are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
More trials for these conditions
Other studies related to the condition(s) this trial covers.